Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by American Century Companies Inc.

Key Points

• American Century Companies Inc. has significantly reduced its stake in Kiniksa Pharmaceuticals, selling 21,085 shares to hold 20,333 shares, a 50.9% decrease in ownership as reported in its latest SEC filing.
• Kiniksa Pharmaceuticals reported a Q2 earnings per share (EPS) of $0.23, exceeding analysts' expectations of $0.18 with a revenue of $156.80 million for the quarter.
• The stock had a price target increase from analysts, with Jefferies raising it to $54.00, while Wells Fargo set it at $42.00, indicating a strong interest in the company’s growth potential.

American Century Companies Inc. cut its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 50.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,333 shares of the company's stock after selling 21,085 shares during the quarter. American Century Companies Inc.'s holdings in Kiniksa Pharmaceuticals International were worth $452,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. GAMMA Investing LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after purchasing an additional 568 shares in the last quarter. Sound View Wealth Advisors Group LLC grew its position in shares of Kiniksa Pharmaceuticals International by 4.0% during the first quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company's stock worth $326,000 after purchasing an additional 568 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Kiniksa Pharmaceuticals International by 6.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,841 shares of the company's stock valued at $432,000 after purchasing an additional 1,380 shares during the period. US Bancorp DE purchased a new position in Kiniksa Pharmaceuticals International during the 1st quarter valued at approximately $33,000. Finally, Knights of Columbus Asset Advisors LLC grew its holdings in Kiniksa Pharmaceuticals International by 2.7% during the 1st quarter. Knights of Columbus Asset Advisors LLC now owns 62,624 shares of the company's stock valued at $1,391,000 after buying an additional 1,658 shares in the last quarter. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals International Trading Down 2.6%

Shares of KNSA stock traded down $0.97 during mid-day trading on Wednesday, reaching $35.89. The stock had a trading volume of 159,668 shares, compared to its average volume of 666,621. The business's fifty day moving average is $31.32 and its 200-day moving average is $26.77. The firm has a market cap of $2.66 billion, a price-to-earnings ratio of 896.60 and a beta of 0.20. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.82 and a 1-year high of $37.25.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. The business had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, insider John F. Paolini sold 29,325 shares of Kiniksa Pharmaceuticals International stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $32.55, for a total value of $954,528.75. Following the sale, the insider owned 57,403 shares in the company, valued at $1,868,467.65. The trade was a 33.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mark Ragosa sold 18,889 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, August 4th. The shares were sold at an average price of $32.89, for a total value of $621,259.21. Following the completion of the sale, the chief financial officer directly owned 27,009 shares of the company's stock, valued at $888,326.01. The trade was a 41.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 562,271 shares of company stock valued at $18,716,309 in the last ninety days. 53.48% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Wells Fargo & Company raised their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday, July 9th. Wall Street Zen raised Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Sunday. Jefferies Financial Group upped their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Finally, Wedbush restated an "outperform" rating and set a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $41.17.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.